House
Create account
Drug reference directory
Drug reference

nab-sirolimus

Antineoplastic agent, mTOR inhibitor

Antineoplastic agent, mTOR inhibitor
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated

Mechanism

Not yet extracted

Related guidelines

Heart failure in diabetes
RSSDI · Cardiology · 2023
Hypertension in adults
ICMR · Cardiology · 2019
Hypertrophic cardiomyopathy
ESC · Cardiology · 2026
Diabetes management in chronic kidney disease
KDIGO · Nephrology · 2022
Type 2 diabetes in adults
NICE · Endocrinology · 2022

Other Unclassified drugs

5-9-tetrahydrocannabinol
0 brands
6-mercaptopurine
0 brands
acetylsalicylic acid
0 brands
acotiamide
0 brands
acoziborole
0 brands
activated charcoal
0 brands
adrenaline
0 brands
adrenochrome monosemicarbazone
0 brands

Ask House about nab-sirolimus

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspaceAsk House about this drug

Textbook-sourced·Sources: Harrison 22e·Updated: 2026-05-10